What is a 483 Form?

A 483 is a form issued by the Food and Drug Administration (FDA) to a manufacturer of a consumable item (such as pharmaceuticals). This form lists observations from an inspector that outlines ways they believe the manufacturer has significantly deviated from current good manufacturing practices (CGMPs). Since the 483 outlines observations, which are subjective, the 483 form is not considered an absolute ruling on the state of a manufacturing facility. Recipients of a 483 should respond to each observation and outline how they will resolve the issue, or face further escalation from the FDA in the form of an official warning letter, a plant shut-down or withholding of a drug approval.

Impact

The Food and Drug Administration presides over all drug approvals in the United States. In addition, because many organizations have international supply chains, the FDA can affect world-wide businesses. Although the FDA has no legal jurisdiction to issue a 483 form outside of the United States, it can halt imports for suppliers with suspect processes and products. A 483 form alone does not mean a pharmaceutical product will not get approved, but without adequate reassurance that hazards have been mitigated, further action will be taken by the FDA. CGMPs relate to the manufacture and testing of all pharmaceutical ingredients, as well as food, diagnostic and medical devices and cover everything from risk assessment techniques to corrective and preventive actions (CAPA), workflows, management of change, proper risk controls and post-market surveillance.

Challenge

Manufacturing pharmaceuticals or other consumable products requires complex processes and stringent safety and security methods. Keeping track of documentation, ensuring changes to a manufacturing process are done safely, and standardizing risk assessment and management methodologies can be challenging for large organizations. The manufacture of a single drug requires numerous risk assessments and safety measures, as well as the design of machinery and processes specific to that product and the hundreds of compounds that it comprises. Lack of a consistent, standard format for quality risk identification, analysis and mitigation can lead to undesirable events, unsafe products and processes and 483 forms or warning letters from the FDA.  Receiving a 483 form is often a signal that a company needs to either improve its Quality Risk Management program or improve the transparency of its risk management.

The Dyadem Solution

The Stature enterprise risk management solution can assist with all aspects of a quality management system, ensuring that risk is properly identified, analyzed and mitigated – before an inspector comes. Stature can provide your organization with a common quality framework, ensuring that everyone is speaking the same quality language, helping develop a unified quality and risk culture and ensuring that you are always aware of the risks that could impact patient safety and your business. The Stature Risk Management, Management of Change and Incident Management modules support multiple workflows that can be configured to any corporate standard and provide a global risk register of all risks across the organization. By allowing you to view risk holistically from the start, Stature can help ensure potential risk is addressed efficiently and effectively, leading to good manufacturing practices for your organization.